Scribd
Upload
28 views1 page

Date: 29th Sep, 2020 Should You Subscribe To The UTI AMC IPO?

UTI AMC is launching its IPO, and the document analyzes whether investors should subscribe. Positives include the growing mutual fund industry and UTI being the third company to list. However, negatives outweigh positives as UTI has consistently lost market share and seen declining profits, assets under management, and return on equity compared to peers. The document recommends waiting for the IPO response and subscription before applying rather than subscribing due to UTI's underperformance.

Uploaded by

Japish Mehta
Copyright
© © All Rights Reserved
We take content rights seriously. If you suspect this is your content, claim it here.
Available Formats
Download as DOCX, PDF, TXT or read online on Scribd
28 views1 page

Date: 29th Sep, 2020 Should You Subscribe To The UTI AMC IPO?

UTI AMC is launching its IPO, and the document analyzes whether investors should subscribe. Positives include the growing mutual fund industry and UTI being the third company to list. However, negatives outweigh positives as UTI has consistently lost market share and seen declining profits, assets under management, and return on equity compared to peers. The document recommends waiting for the IPO response and subscription before applying rather than subscribing due to UTI's underperformance.

Uploaded by

Japish Mehta
Copyright
© © All Rights Reserved
We take content rights seriously. If you suspect this is your content, claim it here.
Available Formats
Download as DOCX, PDF, TXT or read online on Scribd
You are on page 1/ 1

Date: 29th Sep, 2020

Should you subscribe to the UTI AMC IPO?

IPO Season is on. Investors are going frenzy as many IPOs are getting record subscription. UTI
AMC IPO is opening today. Investors are eager to know whether they should buy this IPO or not.
MoneyGain is coming up with an in-depth analysis of the same.

These facts will provide you some light:

Positives:

1. Mutual fund industry is a growing industry and is expected to continue to grow.


2. UTI is going to be the only third company in listing space.
3. The IPO is coming at a cheap valuation as compared to its peers – HDFC & Nippon.

Negatives:

1. Market share of UTI is consistently dropping. It has declined to 5.4% as of Jun-20 from 8.2%
as of Mar-14.
2. AUM has dropped by 15.4% to Rs 1.36 trillion as of Jun-20 from Rs 1.58 trillion as of Jun-19.
3. Consistent decline in management fee: Rs 7.9 billion, Rs 8.8 billion and Rs 9.4 billion in
FY20, FY19 and FY18 respectively.
4. Net profit is in a downtrend: Rs 2.7 billion, Rs 3.5 billion & Rs 4 billion in FY20, FY19 &
FY18 respectively.
5. To add to the woes, the majority of schemes of the AMC are not performing well.
Underperformance will make it hard to bring fresh investments and can lead to
redemptions as well.
6. UTI does not have its own banking channel to promote the sale of its products.
7. AMC has the lowest ROE of just 10%.

We at the MoneyGain don’t see much juice in the IPO as UTI AMC is consistently underperforming
than its peers. Even though it is at a low PE valuation of 26 compared to its peers, we don’t
recommend it. For listing gains, we advise to just wait and check the response and subscription
before applying.

You might also like